Chikungunya vaccine: Valneva completes End-of-Phase 2 meeting with FDA

Valneva SE announced this week that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development plan towards licensure for its unique, single-shot chikungunya vaccine, VLA1553. Regulatory approval will be based on an immunological surrogate (Accelerated Approval Pathway). The main Phase 3 pivotal ["]

The post Chikungunya vaccine: Valneva completes End-of-Phase 2 meeting with FDA appeared first on Outbreak News Today.